UPLIZNA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Spain.

Active ingredients

The drug UPLIZNA contains one active pharmaceutical ingredient (API):

1	Inebilizumab UNII 74T7185BMM - INEBILIZUMAB
	Inebilizumab is a monoclonal antibody that specifically binds to CD19, a cell surface antigen present on pre-B and mature B-cell lymphocytes, including plasmablasts and some plasma cells. Following cell surface binding to B lymphocytes, inebilizumab supports antibody-dependent cellular cytolysis (ADCC) and antibody-dependent cellular phagocytosis (ADCP). B cells are believed to play a central role in the pathogenesis of NMOSD. The precise mechanism by which inebilizumab exerts its therapeutic effects in NMOSD is unknown.
	Read more about Inebilizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
UPLIZNA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
UPLIZNA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG10		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1836547, 1881806
ES	Centro de información online de medicamentos de la AEMPS	1211602001
FR	Base de données publique des médicaments	60878038
IT	Agenzia del Farmaco	050085012
JP	医薬品医療機器総合機構	6399429A1026
LT	Valstybinė vaistų kontrolės tarnyba	1094784
US	FDA, National Drug Code	72677-551